

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

AUG 15 PM 3:53

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>PodestaMattoon</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>1001 G Street, NW</b> Suite <b>900 East</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20001</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>Jeff Cordeau</b>	Telephone <b>202-879-9366</b>	E-mail (optional) <b>jcordeau@podestamattoon.com</b>	5. Senate ID # <b>31680-101</b>
7. Client Name <input type="checkbox"/> Self <b>Biotechnology Industry Organization</b>			6. House ID #

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☒ OR Year End (July 1-De

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date \_\_\_\_\_

11. No Lobby

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$60,000.00</u> <small>Income (nearest \$20,000)</small> Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>EXPENSES</b> relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ <small>Expenses (nearest \$20,000)</small> <b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of <input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 603 the Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162 Internal Revenue Code

Signature

*Jim Cohe*

Date 7/19/2004



Registrant Name: **PodestaMattoon**Client Name: **Biotechnology Industry Organization**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code **CPT** (one per page)

16. Specific Lobbying issues

**H.R.2769, Save Our Seniors Act of 2003,****S.15 , Biodefense Improvement and Treatment for America Act,****S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguards****S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004 ,****S.2384, To amend the Small Business Act to permit business concerns that are owned by venture capital or pension plans to participate in the Small Business Innovation Research Program.****S.2493, Safe IMPORT Act of 2004 ,****FDA drug approval issues**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None**Department of Health & Human Services****Department of Homeland Security****House of Representatives****Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Cohen, Sharon</b>	
<b>Podesta, Anthony</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Date **7/19/2004**



Registrant Name: **PodestaMattoon**Client Name: **Biotechnology Industry Organization**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MED** (one per page)

16. Specific Lobbying issues

**H.R.2769, Save Our Seniors Act of 2003,****S.15 , Biodefense Improvement and Treatment for America Act,****S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguar****S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004 ,****S.2384, To amend the Small Business Act to permit business concerns that are owned by venture capital o  
companies or pension plans to participate in the Small Business Innovation Research Program.****S.2493, Safe IMPORT Act of 2004 ,****FDA drug approval issues**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None**Department of Health & Human Services****Department of Homeland Security****House of Representatives****Senate**


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Cohen, Sharon</b>	
<b>Podesta, Anthony</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Date **7/19/2004**



Registrant Name: PodestaMattoon

Client Name: Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues

**H.R.2769, Save Our Seniors Act of 2003,**

**S.15 , Biodefense Improvement and Treatment for America Act,**

**S.2307, Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguard**

**S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004 ,**

**S.2384, To amend the Small Business Act to permit business concerns that are owned by venture capital op companies or pension plans to participate in the Small Business Innovation Research Program.**

**S.2493, Safe IMPORT Act of 2004 ,**

**FDA drug approval issues**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**Department of Health & Human Services**

**Department of Homeland Security**

**House of Representatives**

**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Cohen, Sharon</b>	
<b>Podesta, Anthony</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date 7/19/2004

